Can a daily microdose of psilocybin calm chronic anxiety?

NCT ID NCT06969170

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial investigates whether a low-dose psilocybin oral solution can safely ease symptoms of generalized anxiety disorder (GAD). Adults aged 18-60 with a GAD diagnosis and moderate-to-severe anxiety will first receive open-label psilocybin for four weeks, then those who respond will be randomly assigned to continue psilocybin or switch to a placebo for another four weeks. Researchers will track side effects, anxiety scores, and brain activity to see if this approach holds promise as a daily treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin oral solution
What this could lead to
If successful, this could point toward a new daily, low-dose treatment option for generalized anxiety disorder.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not hold up in larger studies. Psilocybin can cause side effects, and the placebo comparison is limited to a short double-blind phase.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER (GAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kingston General Health Research Institute

    RECRUITING

    Kingston, Ontario, K7L 2V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.